Hamed Gilzad Kohan
Hamed Gilzad Kohan, PhD
Assistant Professor of Pharmaceutics

Western New England University


  • 2006 – 2013, Doctor of Philosophy (PhD), Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
  • 1994 – 2000, Doctor of Pharmacy (PharmD), School of Pharmacy and Pharmaceutical Sciences, University of Tehran, Iran 



Currently, I am the principal investigator on several research projects including “Synthesis, Characterization, and Pharmacokinetic (PK) Studies of Novel Chemotherapeutic Derivatives”, “Influence of the Pro-inflammatory Cytokines on Expression of the Intestinal P-gp; a Drug Disease Interaction Study”, and “Modulatory Effect of Calcitriol, Vit C, BHA, BHT, and Silibinin on influx protein, ENT1, and efflux pumps, MRP1, MRP5, P-gp in pancreatic cancer cells.

I am primarily interested in Drug Discovery and Development, Physical Pharmacy, Dosage Forms, Biopharmaceutics, Compounding, Pharmacokinetics, and Drug Metabolism, I am equally motivated in taking up courses which are not directly related to my area of expertise, but are broadly within the area of my knowledge.

Research Interest

Pharmacokinetics, Drug discovery, Drug development, Bioavailability and Bioequivalence.


Professional Activities:

2015-Present Assistant Professor of Pharmaceutics Western New England University, Springfield, Massachusetts, USA
2014 – 2015 Assistant Professor of Pharmaceutics Albany College of Pharmacy and Health Sciences, Albany, New York, USA
2013 – 2014 Postdoctoral Research Fellow Albany College of Pharmacy and Health Sciences, Albany, New York, USA
2010-2013 Licensed Pharmacist in Canada Shoppers Drug Mart, Edmonton, Canada
2002 –2006 Manager Quality Control and Research & Development Aburaihan Pharmaceutical Company, Tehran, Iran          


Honors and Awards


  1. Vandhana Muralidharan-Chari, Hamed Gilzad-Kohan, Alex Asimakopoulos, Thangirala Sudha, Stewart Sell, Kannan Kurunthachalam, Mehdi Boroujerdi, Shaker A Mousa1Removal of Therapeutic Drugs by Microvesicles Contributes to Drug Resistance in Cancer Cells., in preparation, 2015
  2. Gilzad-Kohan, M.H; Boroujerdi, M, Time Course and dose dependency of Influx and Efflux Protein Expression after Treatment with Gemcitabine in Pancreatic Cancer Cells. Xenobiotica,2015; 1-11, (doi: 10.3109/00498254.2014.1001809)
  3. Gilzad-Kohan, M.H; Kaur, K.; Jamali, F. A Novel Peptide Pro-drug of Glucosamine with Enhanced Gut Permeability. PLoS One. 2015 May 15;10(5):e0126786. doi: 10.1371/journal.pone.0126786. eCollection 2015
  4. Gilzad-Kohan, M. H.; K. Kaur and Jamali, F. The Antiinflammatory Action and Pharmacokinetics of a Novel Di-Peptide Aminosugar. J Pharm Pharm Sci (www.cspsCanada.org) 16(2) 279 - 288, 2013
  5. Gilzad-Kohan, M. H.; Jamali, F. Glucosamine and adjuvant arthritis: a pharmacokinetic and pharmacodynamic study. Eur. J. Pharm. Sci. 2012, 47, 387-393.
  6. Ibrahim, A.; Gilzad-Kohan, M. H.; Aghazadeh-Habashi, A.; Jamali, F. Absorption and bioavailability of glucosamine in the rat. J. Pharm. Sci. 2012, 101, 2574-2583.
  7. Agahzadeh-Habashi, A.; Gilzad-Kohan, M.; Jamali, F. Glucosamine Dose-Effect Correlation in Adjuvant Arthritis Rat. Journal of Osteoarthritis Cartilage. Submitted 2013.
  8. M. H. D. Kamal Al-Hallak, Muhammad Khan Sarfraz, Shirzad Azarmi, M. H. Gilzad Kohan, Wilson H. Roa, and Raimar Löbenberg, Microcalorimetric Method to Assess Phagocytosis: Macrophage- Nanoparticle Interactions, AAPS J. 2011 March; 13(1): 20–29.





Autoimmune Journal Flyer